Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab + apatinib + SOX for unresectable advanced gastric cancer
ChiCTR2100048020Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Youjiang Medical College for Nationalities
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib, tegafur + gimeracil + oteracil and oxaliplatin in gastric cancer (GC), sponsored by Affiliated Hospital of Youjiang Medical College for Nationalities. Primary endpoints: Progression-free survival (PFS), Overall survival (OS) and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranibtegafur + gimeracil + oteraciloxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100048020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048020.